|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Traditional Chinese medicine in COVID-19显示文摘COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2(SARSCo V-2)has spread across the globe,posing an enormous threat to public health and safety.Traditional Chinese medicine(TCM),in combination with Western medicine(WM),has made important and lasting contributions in the battle against COVID-19.In this review,updated clinical effects and potential mechanisms of TCM,presented in newly recognized three distinct phases of the disease,are summarized and discussed.By integrating the available clinical and preclinical evidence,the efficacies and underlying mechanisms of TCM on COVID-19,including the highly recommended three Chinese patent medicines and three Chinese medicine formulas,are described in a panorama.We hope that this comprehensive review not only provides a reference for health care professionals and the public to recognize the significant contributions of TCM for COVID-19,but also serves as an evidence-based in-depth summary and analysis to facilitate understanding the true scientific value of TCM. | Ming Lyu Guanwei Fan Guangxu Xiao Taiyi Wang Dong Xu Jie Gao Shaoqin Ge Qingling Li Yuling Ma Han Zhang Jigang Wang Yuanlu Cui Junhua Zhang Yan Zhu Boli Zhang | 2021 | Acta Pharmaceutica Sinica B2021，11，11： | 14 |
| 2 | 新型冠状病毒肺炎疫情下快速动态化制订循证中医指南的思考显示文摘鉴于新型冠状病毒肺炎疫情下证据呈现快速累积和动态变化的特点,在制订中医循证指南时需借鉴WHO快速指南方法并充分体现中医药证据特色。其中,在构建指南证据体时需系统检索新冠肺炎相关及间接疾病相关研究证据,并充分收集古籍文献和名老专家共识等经验证据,以最大程度发掘中医治疗的特色和优势。在形成指南推荐意见时,需要按照证据质量“就高不就低”原则,对直接与间接、研究与经验证据共存状态下的多来源证据进行择优综合与推荐。快速制订中医指南并实现动态化更新是应对新冠肺炎临床需求不断变化的必要措施,是中医参与突发公共卫生决策的重要依据。 | 梁宁 陈雅馨 李慧珍 李晓玲 王晶亚 焦丽雯 刘国秀 刘斌 张海力 宗星煜 王燕平 史楠楠 | 2022 | 中国中西医结合杂志2022，42，2： | 4 |
| 3 | Chinese herbal medicine and COVID-19: quality evaluation of clinical guidelines and expert consensus and analysis of key recommendations显示文摘Objective:To systematically review the clinical practice guidelines(CPGs)for the treatment of patients with coronavirus disease 2019(COVID-19)using Chinese herbal medicine(CHM),assess the methodological quality as well as clinical credibility and implementability of specific recommendations,and summarize key recommendations.Methods:As of April 2022,we conducted a comprehensive search on major electronic databases,guideline websites,academic society websites,and government websites to assess the methodological quality and clinical applicability of the included CPGs using the Appraisal of Guidelines for Research and Evaluation(AGREE)II tool and Evaluation-Recommendations EXcellence(AGREE-REX)instructions,respectively.Results:The search yielded 61 CPGs,which were mostly published in 2020;moreover,98.4%of the CPGs were published in China.Only five CPGs achieved a high-quality AGREE II rating;further,six CPGs could be directly recommended,with most of the CPGs still showing much room for improvement.CPGs had a low overall score in the AGREE-REX evaluation,with the domains of clinical applicability,values and preferences,and implementability being standardized in 21.80%±12.56%,16.00%±11.81%,and 31.33%±14.55%of the CPGs,respectively.Five high-quality CPGs mentioned 56 Chinese herbal formulas.Half of the recommendations had moderate or strong evidence level in the GRADE evaluation.The most frequently recommended herbal medicines were Lianhua Qingwen granule/capsule and Jinhua Qinggan granule;however,the strength of recommendation for each prescription varied across CPGs and populations.Conclusions:The overall quality of current CPGs for COVID-19 for CHM still needs to be improved;moreover,the strength of the evidence remains to be standardized across CPGs. | Qingyong Zheng Ya Gao Lu Xiong Hengyi Huang Junfen Li Guoyuan OuYang WulayinSaimire Jingjing Yang Yu Zhang Xiaopeng Wang Xiaofeng Luo | 2022 | Acupuncture and Herbal Medicine2022，2，3： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员